Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2007 1
2009 1
2010 1
2011 1
2012 2
2013 2
2014 1
2016 3
2020 2
2021 6
2022 6
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity.
Anfray C, Mainini F, Digifico E, Maeda A, Sironi M, Erreni M, Anselmo A, Ummarino A, Gandoy S, Expósito F, Redrado M, Serrano D, Calvo A, Martens M, Bravo S, Mantovani A, Allavena P, Andón FT. Anfray C, et al. Among authors: serrano d. J Immunother Cancer. 2021 Sep;9(9):e002408. doi: 10.1136/jitc-2021-002408. J Immunother Cancer. 2021. PMID: 34531246 Free PMC article.
PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A. Exposito F, et al. Among authors: serrano d. Cancer Res. 2023 Aug 1;83(15):2513-2526. doi: 10.1158/0008-5472.CAN-22-3023. Cancer Res. 2023. PMID: 37311042
YES1 Is a Druggable Oncogenic Target in SCLC.
Redin E, Garrido-Martin EM, Valencia K, Redrado M, Solorzano JL, Carias R, Echepare M, Exposito F, Serrano D, Ferrer I, Nunez-Buiza A, Garmendia I, García-Pedrero JM, Gurpide A, Paz-Ares L, Politi K, Montuenga LM, Calvo A. Redin E, et al. Among authors: serrano d. J Thorac Oncol. 2022 Dec;17(12):1387-1403. doi: 10.1016/j.jtho.2022.08.002. Epub 2022 Aug 18. J Thorac Oncol. 2022. PMID: 35988891 Free article.
Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies.
Palanca-Ballester C, Rodriguez-Casanova A, Torres S, Calabuig-Fariñas S, Exposito F, Serrano D, Redin E, Valencia K, Jantus-Lewintre E, Diaz-Lagares A, Montuenga L, Sandoval J, Calvo A. Palanca-Ballester C, et al. Among authors: serrano d. Cancers (Basel). 2021 Jun 16;13(12):3016. doi: 10.3390/cancers13123016. Cancers (Basel). 2021. PMID: 34208598 Free PMC article. Review.
Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells.
Martín-Otal C, Lasarte-Cia A, Serrano D, Casares N, Conde E, Navarro F, Sánchez-Moreno I, Gorraiz M, Sarrión P, Calvo A, De Andrea CE, Echeveste J, Vilas A, Rodriguez-Madoz JR, San Miguel J, Prosper F, Hervas-Stubbs S, Lasarte JJ, Lozano T. Martín-Otal C, et al. Among authors: serrano d. J Immunother Cancer. 2022 Aug;10(8):e004479. doi: 10.1136/jitc-2021-004479. J Immunother Cancer. 2022. PMID: 35918123 Free PMC article.
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E, Garmendia I, Lozano T, Serrano D, Senent Y, Redrado M, Villalba M, De Andrea CE, Exposito F, Ajona D, Ortiz-Espinosa S, Remirez A, Bertolo C, Sainz C, Garcia-Pedrero J, Pio R, Lasarte J, Agorreta J, Montuenga LM, Calvo A. Redin E, et al. Among authors: serrano d. J Immunother Cancer. 2021 Mar;9(3):e001496. doi: 10.1136/jitc-2020-001496. J Immunother Cancer. 2021. PMID: 33658304 Free PMC article.
29 results